<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: This article presents an overview of the most recent and important strategies to reduce secondary brain damage </plain></SENT>
<SENT sid="1" pm="."><plain>RECENT FINDING: There is currently no magic bullet available to protect the brain after neuronal injury </plain></SENT>
<SENT sid="2" pm="."><plain>This is related to the complex pathophysiology of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, which makes it unlikely that a single pharmacological intervention results in sustained neuroprotection </plain></SENT>
<SENT sid="3" pm="."><plain>Analyses of clinical studies reveal that <z:hpo ids='HP_0011009'>acute</z:hpo> physiologic derangements (e.g. <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0002615'>hypotension</z:hpo>, hypoxemia, <z:mp ids='MP_0002318'>hypercapnia</z:mp>, <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>) are the most important predictors of unfavorable outcome after brain injury and have to be treated </plain></SENT>
<SENT sid="4" pm="."><plain>The effectiveness of <z:chebi fb="0" ids="38867">anesthetic agents</z:chebi> to extend the ischemic tolerance of neurons has been demonstrated in experimental settings, but such benefits have not been demonstrated in humans </plain></SENT>
<SENT sid="5" pm="."><plain>The effectiveness of osmodiuretics to decrease <z:e sem="disease" ids="C0151740" disease_type="Disease or Syndrome" abbrv="">elevated intracranial pressure</z:e>, a factor with relevance to outcome, has been demonstrated </plain></SENT>
<SENT sid="6" pm="."><plain>Infusion of <z:chebi fb="131" ids="25107">magnesium</z:chebi> in patients with subarachnoidal <z:mp ids='MP_0001914'>hemorrhage</z:mp> can reduce the occurrence of delayed <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> caused by <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebrovascular spasm</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The prophylactic administration of <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> should be avoided </plain></SENT>
<SENT sid="8" pm="."><plain>While the positive effects of <z:hpo ids='HP_0011010'>chronic</z:hpo> administration of <z:chebi fb="0" ids="35664">statins</z:chebi> to reduce the incidence of <z:hpo ids='HP_0001297'>stroke</z:hpo> has been demonstrated in several clinical studies, the protective effect of <z:hpo ids='HP_0011009'>acute</z:hpo> administration of <z:chebi fb="0" ids="35664">statins</z:chebi> after a cerebral insult has do be defined </plain></SENT>
<SENT sid="9" pm="."><plain>SUMMARY: Control of physiological variables, avoidance of <z:hpo ids='HP_0001945'>hyperthermia</z:hpo>, intensive control of plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations, use of <z:chebi fb="0" ids="38867">anesthetic agents</z:chebi> and osmodiuretics to control intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> and the possible prophylactic administration of <z:chebi fb="131" ids="25107">magnesium</z:chebi> in patients at risk of vasospasm and of <z:chebi fb="0" ids="35664">statins</z:chebi> in patients with cerebrovascular risk factors are currently the most important strategies to reduce neuronal injury </plain></SENT>
</text></document>